Applied dna biotherapeutics subsidiary linearx and evvivax publish additional positive animal proof-of-concept data supporting lineardna™ platform as a unique approach to veterinary dna vaccine development

Stony brook, n.y.--(business wire)---- $apdn #lnp--applied dna sciences, inc. (nasdaq: apdn) (the “company”), a leader in cell-free, enzymatic dna production, today announced the publication of a manuscript containing data demonstrating that a lineardna vaccine successfully elicited neutralizing antibodies and cellular immunity against sars-cov-2. the manuscript, authored by linearx, the company's majority-owned biotherapeutics subsidiary, and linearx's development partner, evvivax, s.r.l., further establishe
APDN Ratings Summary
APDN Quant Ranking